MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for the second quarter ended June 30, 2025, compared to $699 million for the same period of 2024. “The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,” said Kevin Conroy, chairman and CEO. “In the second quarter, we delivered answers to more patients t
Related Questions
How did the company's gross margin and operating expenses change versus the prior year and forecast?
What is the updated outlook for Q3 and FY 2025 earnings guidance, and is there any revision to the full-year guidance?
Were there any notable changes in cash flow, capital expenditures, or balance sheet strength in the quarter?
Is there any insider buying or selling activity around the release that might signal management sentiment?
What are the implications of the increased patient volume for market share and long‑term revenue trajectory?
Did the $112M revenue increase beat analyst expectations and how will it affect the forward P/E multiple?
What was the breakdown of revenue growth by product line (e.g., Cologuard vs other diagnostics) and geographic region?
How is the market pricing the latest earnings surprise, and are short‑term trading opportunities emerging from the news?
How does Exact Sciences' Q2 2025 performance compare to peer averages in the cancer diagnostics sector?
Did the company disclose any new partnerships, regulatory updates, or pipeline developments that could impact future growth?